Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
16.52
-0.19 (-1.14%)
Aug 14, 2025, 11:24 AM - Market open

Zenas BioPharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
Net Income
-177.01-156.99-37.12-119.28
Depreciation & Amortization
0.10.140.110.08
Asset Writedown & Restructuring Costs
--101
Loss (Gain) From Sale of Investments
-1.92-0.6--
Stock-Based Compensation
19.7710.823.50.74
Other Operating Activities
0.831.531.0343.85
Change in Accounts Payable
-0.3911.74-0.421.09
Change in Other Net Operating Assets
10.113.69-7.626.88
Operating Cash Flow
-148.41-119.67-30.53-65.65
Capital Expenditures
-0.09-0.13-0.02-0.2
Sale (Purchase) of Intangibles
----2
Investment in Securities
-228.97-30.42--
Investing Cash Flow
-229.06-30.55-0.02-2.2
Long-Term Debt Issued
--20-
Net Debt Issued (Repaid)
--20-
Issuance of Common Stock
242.57240.910.12-
Other Financing Activities
-4.91-6.33--
Financing Cash Flow
237.65412.9620.1259.39
Foreign Exchange Rate Adjustments
-0.20.160.08-0.04
Net Cash Flow
-140.01262.89-10.35-8.5
Free Cash Flow
-148.5-119.81-30.55-65.85
Free Cash Flow Margin
-989.99%-2396.10%-61.09%-
Free Cash Flow Per Share
-4.46-9.08-19.95-44.13
Levered Free Cash Flow
-85.22-60.01-17.64-
Unlevered Free Cash Flow
-85.22-60.01-17.64-
Change in Working Capital
9.7125.43-8.047.97
Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q